Researchers at City of Hope have data pointing to the limitations of Signatera, a popular "liquid biopsy" or blood draw test that is used to detect the recurrence of colorectal cancer in patients who have had their disease surgically removed. The study was published March 8 in JAMA Open Network.
“A liquid biopsy measuring circulating tumor DNA is a novel way to test for residual disease in patients who have recently received curative resection for colon cancer. Identifying early disease recurrence is important as it may allow for potential curative interventions,” said Marwan Fakih, M.D., co-director of City of Hope’s Gastrointestinal Cancer Program and lead author of the new study.
Fifteen patients experienced colorectal cancer recurrence. Within this group, standard-of-care surveillance was better at identifying early disease. For example, Signatera did not identify patients who had early recurrence in the lungs. Three patients received a negative ctDNA test, but standard-of-care surveillance techniques identified disease recurrence in their lungs.
“Imaging remains the most important surveillance assay in the follow-up of resected colorectal cancers. Clinicians should continue to abide by National Comprehensive Cancer Network guidelines. For those who decide to implement ctDNA into their surveillance algorithm, they should be aware of the limitations associated with this assay,” Fakih said, referencing current clinical trials elsewhere where clinicians are de-intensifying chemotherapy based on a negative ctDNA test by Signatera.
It may be premature to base treatment decisions solely on ctDNA results “given the limitations of Signatera sensitivity,” said Fakih, the Judy & Bernard Briskin Distinguished Director of Clinical Research and a professor in City of Hope’s Department of Medical Oncology & Therapeutics Research.
Fakih added that using liquid biopsies to identify disease recurrence is an attractive, noninvasive option. Liquid biopsy is convenient and, unlike CT, does not expose patients to low doses of radiation. However, scientists are still working to develop a reliable and sensitive liquid biopsy to detect colorectal cancer recurrence. Nevertheless, there is promise.
“ctDNA was able to identify several recurrences in the liver and lymph nodes ahead of imaging,” Fakih said. “For now, ctDNA can be considered, if any at all, as a complement to the standard approach recommended by the NCCN, but one must be cognizant of its limitations.”